An international collaboration between the Weizmann Institute, UC San Diego, and Micronoma provides the most comprehensive characterization of fungi in cancer to date, discovering synergistic interactions with bacteria and furthering the role of mycobiome as an...
Todd Czerwinski will oversee the development and execution of market access, strategic partnerships and sales as the company rolls out its groundbreaking early cancer diagnosis platform SAN DIEGO, May 24, 2022 — Micronoma, the first cancer detection biotech company...
Microbiome-driven liquid biopsy company draws international recognition for using innovative technology to enable early cancer detection and improve chances of survival SAN DIEGO, Nov. 3, 2021 /PRNewswire/ — Micronoma, the first cancer detection biotech company...
Machine learning and microbiome-driven liquid biopsy technology draws recognition for improving early cancer diagnosis and chances of survival August 2, 2021 – San Diego, Calif. Micronoma, the first cancer detection biotech company to diagnose cancer at an early...
Research uses circulating microbiome biomarkers, machine learning for early detection July 20, 2021 – San Diego, Calif. Micronoma, the first cancer detection company to harness tumor-associated circulating microbial biomarkers to diagnose cancer at an early stage...
Jennifer Wargo, M.D., leads research on link between microbiome and cancer treatment and recently co-authored Science review with Micronoma founders San Diego, Calif. (April 6, 2021) – San Diego, Calif. Micronoma, the first cancer detection biotech company that...
